Blar i forfatter "Geisen, Christof"

Viser treff 1-2 av 2

    • An HPA-1a-positive platelet-depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo-controlled, single-center, phase 1/2 proof-of-concept study 

      Geisen, Christof; Kjær, Mette; Fleck, Erika; Skogen, Bjørn; Armstrong, Roisin; Behrens, Frank; Bhagwagar, Zubin; Braeuninger, Susanne; Mörtberg, Anette; Olsen, Klaus Juel; Scafer, Stephan Martin Gaston; Walter, Carmen; Seifried, Erhard; Wikman, Agneta; Kjeldsen-Kragh, Jens; Koehm, Michaela (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-12-22)
      Background: Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is a rare and potentially life-threatening bleeding disorder of the fetus/newborn. Antibodies against human platelet antigen 1a (HPA-1a) are associated with the most frequent FNAIT cases. There are no approved therapies for FNAIT prevention or treatment. RLYB211 is a polyclonal HPA-1a hyperimmune IgG being developed to prevent ...

    • Strategies to develop a prophylaxis for the prevention of HPA-1a immunization and fetal and neonatal alloimmune thrombocytopenia 

      Kjær, Mette; Geisen, Christof; Akkøk, Cigdem Ahaein; Wikman, Agneta; Sachs, Ulrich; Bussel, James B.; Nielsen, Kaspar; Walles, Katarina; Curtis, Brian R.; Vidarsson, Gestur; Järås, Kerstin; Skogen, Bjørn (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-12-31)
      Anti-HPA-1a-antibodies are the main cause of fetal and neonatal alloimmune thrombocytopenia (FNAIT) which may result in intracranial hemorrhage (ICH) and death among fetuses and newborns. Advances in understanding the pathogenesis of FNAIT and proof of concept for prophylaxis to prevent immunization suggest that development of hyperimmune anti-HPA-1a IgG aimed at preventing immunization against ...